BARI-STEP Trial: Semaglutide Reverses Post-Bariatric Surgery Weight Regain in First Randomized Controlled Trial

A landmark clinical trial published in Nature Medicine on May 22, 2026, has established a major new therapeutic paradigm in obesity care. The BARI-STEP trial is the first double-blinded, randomized, placebo-controlled trial evaluating the use of semaglutide (2.4 mg, Wegovy) in patients who experienced suboptimal weight loss or weight regain following metabolic and bariatric surgery (MBS). The results show that semaglutide is highly effective at reversing post-surgical failure, offering a non-invasive alternative to high-risk revision surgeries.

The Post-Surgical Challenge

Metabolic and bariatric surgery (such as sleeve gastrectomy and gastric bypass) is historically the gold standard for severe obesity. However, it is not a permanent cure:

• Approximately one in five (20%) of the 500,000 patients who undergo bariatric surgery worldwide each year experience poor weight loss or subsequent weight regain.
• Historically, patients who responded sub-optimally had limited options: lifestyle interventions (which yield poor results in this cohort) or secondary/revision surgery, which carries significantly higher surgical risks, is invasive, and is inaccessible to the vast majority.

Remarkable Clinical Efficacy

Led by Dr. Janine Makaronidis at the University College London (UCL) Centre for Obesity Research, the BARI-STEP trial followed 70 patients over 68 weeks. Patients were randomized to weekly semaglutide 2.4 mg or placebo, alongside standardized lifestyle and dietary support. The results were stark:

• 10% Weight Loss: 85% of patients taking semaglutide lost at least 10% of their body weight, compared to just 7% in the placebo group.
• 15% Weight Loss: 62% of patients on semaglutide lost at least 15% of their body weight, compared to 7% on placebo.
• 20% Weight Loss: 47% of patients on semaglutide achieved a massive 20% or greater weight loss, compared to only 3% on placebo.
• Body Composition Quality: Crucially, body composition analyses showed that the weight loss was driven almost entirely by body fat reduction, rather than muscle mass loss.
• Cardiometabolic Benefits: The semaglutide cohort showed significant improvements in blood pressure, blood glucose levels, cholesterol, and self-reported quality of life. Side effects were consistent with standard semaglutide therapies (primarily mild-to-moderate gastrointestinal symptoms like nausea).

Market and Investment Implications

Dr. Janine Makaronidis highlighted the future of obesity medicine:

"These findings strengthen the case for using semaglutide in people who do not respond well to bariatric surgery, offering an alternative to repeat operations. They also suggest that combining surgery with weight-loss medicines is an important approach to treating severe obesity."

For investors, this study has two major implications:

1. Total Addressable Market (TAM) Expansion: Instead of GLP-1s being viewed purely as a competitor to bariatric surgery (which has seen a 34% decline in volume), this trial proves that GLP-1s are a highly necessary complement to surgery. This expands the long-term addressable patient base to include the millions of historical bariatric surgery patients worldwide who are experiencing weight regain.
2. Reduced Demand for Revision Surgeries: Medical device companies that specialize in bariatric revision instruments will face a severe decline in demand, as non-invasive weekly injections replace high-risk secondary operations.